Research in the Media

Our Researchers in the News and on Social Media

Dr. Carolyn Baglole

Dr. Carolyn Baglole was interviewed about her recent grant entitled “Prognostic and therapeutic utility of human antigen R (HUR) in idiopathic pulmonary fibrosis”. Her project received 2 year funding from Boehringer-Ingleheim’s Innovation in Understanding ILD (BUILD) program.

Carolyn Baglole hopes to unravel the mystery of idiopathic pulmonary fibrosis, a fatal lung disease that affects some 15,000 Canadians. She received funding from Boehringer Ingelheim's Innovation in Understanding ILD (BUILD) program. 

Dr. Elizabeth Fixman

Dr. Elizabeth Fixman and Dr. Brian Ward (IDIGH Program at RI-MUHC) co-authored a study in the Journal of Leukocyte Biology demonstrating that STAT6-IP reduces the development of allergic-type lung inflammation and airway hyperresponsiveness in mice re-challenged with respiratory syncytial virus (RSV). (2017)


Dr. Russell Hepple

Dr. Russell Hepple was interviewed by the New York Times about his work with octogenerian athlete Ed Whitlock. Dr. Hepple performed tests on Whitlock at McGill and found Whitlock has an exceptional VO2 max (54 at age 81) and largely preserved number of motor muscle units. A study by Dr. Russell Hepple and Dr. Tanja Taivassalo that showed exercise can lower the risk of muscle wasting associated with aging was also featured in the New York Times (Dec and Mar 2016).

hepple_2016_3 hepple_2016_1  hepple_2016_2

Dr. Bruce Mazer

Pediatric allergy and immunology specialists Dr. Bruce Mazer and Dr. Moshe Ben-Shoshan (Montreal Children’s Hospital) started the GET-FACTS (Genetics, Environment and Therapies: Food Allergy Clinical Tolerance Studies) study in 2012. The program is having good success with helping children with milk allergies build up tolerance to milk protein by introducing the allergen very slowly into the diet. They were interviewed by CTV, La Presse, Radio-Canada, 98,5 fm, the Gazette, CJAD and Le Devoir (2016).

mazer_2016_milk_1 mazer_2016_milk_3 mazer_2016_3 mazer_2016_4

Dr. Larry Lands

A new study (Journal of Cystic Fibrosis 2016) led by a team from the Research Institute of the McGill University Health Centre (RI-MUHC) and Cystic Fibrosis Canada reinforces the benefits of newborn screening for Cystic Fibrosis patients. Children with Cystic Fibrosis who are diagnosed through newborn screening are healthier and benefit more from new treatments.

lands_2016CF_1   lands_2016CF_2   lands_2016CF_3   lands_2016CF_4   lands_2016CF_5 Newborn screening for cystic fibrosis has been going on for up to nine years elsewhere in Canada and for decades in some places in the United States; Quebec should follow suit, Dr. Larry Lands writes

 Dr. Dao Nguyen

Dr. Nguyen’s research team discovered that there are variants of Pseudomonas aeruginosa, a bacteria commonly found in Cystic Fibrosis patients, that can cause a lot of inflammation (Science Advances 2015). In some cases, that inflammation leads to the need for lung transplants. Nguyen’s team is the first to make the connection between the bacteria and inflammation.

Nguyen_2015CF_1   Nguyen_2015CF_2   Nguyen_2015CF_3   Nguyen_2015CF_4   Nguyen_2015CF_5   Nguyen_2015CF_6

 Dr. Christine McCusker

Dr. Elizabeth Fixman developed STAT6-IP, a chimeric peptide with the ability to enter cells and disrupt activity of the STAT6 transcription factor. STAT6 has been show to inhibit aberrant Th2 responses in the airways of preclinical models of respiratory syncytial virus infection (Eur J Immunol 2014) and asthma (J Immunol 2007; Clin Exp Allergy 2011; Mucosal Immunol 2015). The latter publication by Dr. Christine McCusker received significant media attention. This work was also selected for one of the top ten scientific breakthroughs of 2015 selected by Québec Science and Dr. Christine McCusker was nominated as the Feb 2016 Researcher of the Month by Canadians for Health Research

McCusker_Stat6   McCusker_Stat6_2   McCusker_Stat6_3  McCusker_Stat6_4   McCusker_Stat6_5   McCusker_Stat6_6  McCusker_Stat6_7   McCusker_Stat6_8   McCusker_Stat6_9   McCusker_Stat6_10   McCusker_Stat6_11

 Dr. Arnold Kristof

Dr. Arnold Kristof participated in the Tuberous Sclerosis Alliance 50K Research Challenge. Watch his video below.

 Dr. Bruce Mazer

Dr. Bruce Mazer explains how the Learning Early about Peanut Allergy (LEAP) trial is changing our approach to peanut allergy. The study (NEJM 2015) found that infants (between 4−11 months) who consumed at least 6 grams of peanut per week were significantly less likely to develop an allergy by 5 years of age, compared to infants who avoided peanut entirely.

mazer_peanut2015_1 mazer_peanut2015_2  mazer_peanut2015_3

 Dr. Basil Petrof

Innovation at the Glen: the CFI talks to our researchers (February 2015)

Basil Petrof: Accelerating new treatments for respiratory diseases  – Podcast

Basil Petrof heads the program for translational research in respiratory diseases at the Research Institute of the McGill University Health Centre. His research group recently participated in a clinical trial that proved the efficacy of a new therapy that burns away the muscle tissue in the lungs of asthmatic patients to help open their airways. It’s this kind of cutting-edge discovery that Petrof expects will move more rapidly from concept to proven treatment thanks to the new facilities at the RI-MUHC.

 Dr. Maziar Divangahi

A study by Dr. Maziar Divangahi (Immunity 2014) revealed that a drug that inhibits PGE2 increases survival of mice infected with H1N1 flu virus. This finding paves the way for urgently needed novel therapies that may be effective against the flu and other viral infections.

divangahi_Mcgillnews  divangahi_Mcgillnews2   divangahi_Mcgillnews3  divangahi_Mcgillnews4  divangahi_Mcgillnews5

Dr. Basil Petrof 

Patients Referred to Neurologists with Respiratory Symptoms: Is it Pompe Disease? (Podcast, October 2014)

Listen to the podcast here

 Dr. Dao Nguyen

Dr. Dao Nguyen’s investigated the behavior of Pseudomonas aeruginosa, a common bacteria in patients with Cystic Fibrosis. Her research (Science 2011) identified that when bacteria are starved, they develop a starvation-signaling stringent response, which allows them to better adapt and survive. This research showed that inactivating this protective mechanism can sensitize biofilms to various antibiotics, thus providing new insights on the mechanisms of antibiotic tolerance.

Nguyen_2011PA_1   Nguyen_2011PA_2   Nguyen_2011PA_3